⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Glecaprevir/pibrentasvir

گلکاپرویر/پیبرنتاسویر

⚠ Unverified

🦠 Antiinfectives For Systemic UsePangenotypic HCV direct-acting antiviral

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:No specific problem stated 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA209394 ATC J05AP57

Market / country: 🇺🇸 USA

Mavyret (US)

🧮 Dose calculator

Disease / regimen

Chronic hepatitis C · Regimen source: FDA Mavyret · 2.3 FDA Mavyret · 2.4

• Duration per Tables 1–2 (experienced or transplant 12–16 weeks). 3–<12 y and <45 kg: weight-based pellets. No adjustment for any renal impairment. FDA Mavyret · 2.2 FDA Mavyret · 2.6 FDA Mavyret · 2.4

Formulation

Age *

Weight (kg) *

Enter age and weight.

🛡️ Safety & information

Contraindications

⛔ Moderate or severe hepatic impairment (Child-Pugh B/C) or prior hepatic decompensation; concomitant atazanavir or rifampin. FDA Mavyret · 4

Warnings

• Boxed warning: HBV reactivation in HCV/HBV co-infection (sometimes fulminant hepatitis and death) — test HBsAg and anti-HBc first. FDA Mavyret · Boxed Warning
• Hepatic decompensation/failure in advanced cirrhosis. FDA Mavyret · 5.2

Formulations

100 mg glecaprevir / 40 mg pibrentasvir tablet — tablet 🇺🇸 USA FDA Mavyret · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Mavyret · 8.1
“Risk Summary No adequate human data are available to establish whether or not MAVYRET poses a risk to pregnancy outcomes.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Mavyret · 8.2
“When administered to lactating rodents, the components of MAVYRET were present in milk, without effect on growth and development observed in the nursing pups (see Data ) .”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Mavyret · 8.4
“No dosage adjustment of MAVYRET is required in pediatric patients 12 years and older or weighing at least 45 kg.”
👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Mavyret · 8.5
“No dosage adjustment of MAVYRET is warranted in geriatric patients [see Clinical Pharmacology ( 12.3 ) ] .”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA209394
DailyMed (FDA label)FDA Mavyret
MedlinePlus (NIH)❌ None
WHO ATC/DDDJ05AP57
Darooyab (Iran)❌ None

🇮🇷 Not found in Iran list Darooyab · search

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Mavyret · 3 FDA Mavyret · 2.3 FDA Mavyret · 2.4 FDA Mavyret · 2.2 FDA Mavyret · 2.6 FDA Mavyret · 4 FDA Mavyret · Boxed Warning FDA Mavyret · 5.2 FDA Mavyret · SPL approval / marketing category FDA Mavyret · 8.1 FDA Mavyret · 8.2 FDA Mavyret · 8.4 FDA Mavyret · 8.5
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · search
Clinical review⚠ Unverified

🔗 Similar drugs

For the same diseases

Eltrombopag Ledipasvir/sofosbuvir Ribavirin Sofosbuvir + velpatasvir